Oral delivery is still the preferred route of administration for most approved, commercially available products. Thanks to the popularity of the dosage form, demand for oral solid drugs, or OSDs, continues to rise, and market research anticipates that there will be further innovations in the field to help overcome the challenges associated with the rising complexity of APIs…

So far, 2025 has been financially challenging for the biopharmaceutical and biotech sectors — with limited access to capital and lean financing on offer — further complicated by macroeconomic uncertainty…

Marking a highlight of the year for the biotechnology industry, the BIO International Convention will convene once again in Boston, Mass., and is set to offer visitors four days of networking events and expert-driven sessions…

Novel therapeutic modalities, such as cell, gene, and nucleic acid therapies, are offering more effective, personalized treatment options to patients with chronic and/or rare diseases that were, not too long ago, considered to be untreatable…

CPHI Americas has wrapped for 2025, closing its doors at noon (EST) on May 22 after having welcomed over 3,925 attendees and 370 exhibitors, as well as 16 start-ups and 82 speakers…

As the month of May marches on, the city of Philadelphia prepares itself to once again play host to CPHI — this year under its new guise of CPHI Americas. For 2025, the event organizers have updated the name of the show to reflect the broader audience, which incorporates Latin America and Canada in addition to North America…

Glucagon-like peptide-1 (GLP-1) receptor agonists first penetrated the market 20 years ago when exenatide (Byetta, originally developed by Amylin Pharmaceuticals and Eli Lilly) gained regulatory approval as a novel treatment option for type 2 diabetes…

For decades, successful pharmaceutical manufacturing has been judged on scale. Nowadays, higher precedence is being given to speed, coping with complexity, and customization…

CDMO partnerships are great when they are successful, but what happens when they falter? The complexity of modern outsourcing partnerships means that failure is often costly, with consequences that can ripple across timelines, budgets, and reputations…

Biopharma companies are increasingly dependent on CDMOs to streamline production, enhance efficiency, and accelerate drug development. As therapies become more complex and regulatory demands grow, the ability to outsource manufacturing to a trusted partner has never been more essential…

Pharmaceutical manufacturing is the backbone of global healthcare, yet its environmental footprint is a growing concern. The sector is responsible for significant greenhouse gas emissions, excessive water consumption, and large-scale hazardous waste production…

India’s pharmaceutical industry has long been synonymous with cost-effective pharmaceutical manufacturing - particularly when it comes to generic drugs. In recent years, India has been making a significant shift from low-cost generic drug production into CDMO services…

The global biologics market is expected to reach USD 720 bn by 2030, fueled by increasing demand for biologics, biosimilars, and advanced therapies. It is undoubtedly an area of keen interest for CDMOs that specialize in biopharmaceutics...

As the demand for advanced therapies continues to grow, CDMOs are fast becoming the solution for biopharma companies that need specialized expertise and capabilities that are scalable for their drug development and commercialization...

The CDMO industry saw significant growth in 2024, as biotech and pharmaceutical companies continued the trend toward outsourcing R&D activities. This surge was evident in the global CDMO market value, which ended the year with a valuation of USD 185 billion…

Overall, 2024 was a good year to be working in the CDMO industry, but will the outlook stay positive for 2025? Forecasts predict a steady rise in continuing growth trends from 2024, with estimates indicating the global pharmaceutical CDMO market is set to grow from USD 184.90 bn in 2024 to USD 197.40 bn in 2025…

The term CDMO has become ubiquitous in the pharmaceutical industry over the past decade, but is it merely a buzzword or does it represent a genuine paradigm shift?

If you were to launch a biopharma startup today, where would you find the skills, talent, and space to bring your vision to life? Biopharma incubators are usually the answer…

Last month, hedge fund Starboard Value acquired a $1 bn stake in Pfizer, at the same time, sharply criticizing the company's management for recent underperformance and strategic missteps…

As the 2024 U.S. election between Donald Trump and Kamala Harris approaches, the biopharma industry is keenly watching how each candidate's policies could shape the future of the sector…